Dernière mise à jour :
07/03/2025
Stabilité et compatibilité des médicaments

Bienvenue dans Stabilis.
Si vous désirez recevoir la newsletter trimestrielle, indiquez votre adresse email.

Inscrivez-vous

Pour toute question ou remarque, contactez : infostab@stabilis.org

Base de données  
Références bibliographiques : 2805
Molécules : 866
Classes pharmacologiques : 46
Stabilités en solution : 6468
Stabilités en mélange : 1254
Compatibilités : 12626
Noms commerciaux : 4740
Nouveautés - Molécules  
Vitamine Forme dermique Pyridoxine hydrochloride 04/03/2025
Antiinflammatoire Forme dermique Hydrocortisone acetate 04/03/2025
Anticancéreux injectable Dostarlimab 03/03/2025
Hormone Gouttes nasales Desmopressine acetate 12/02/2025
Antihypertenseur Solution buvable Olmesartan medoxomil 12/02/2025
Divers Forme dermique Hydroquinone 13/11/2024
Divers Forme dermique Enoxolone 13/11/2024
Antibiotique Forme dermique Dapsone 13/11/2024
Divers Forme dermique Adapalene 13/11/2024
Antibiotique Forme dermique Clarithromycin 18/10/2024
Divers Collyre Methylprednisolone sodium succinate 08/07/2024
Divers Forme dermique Dutasteride 12/06/2024
Divers Forme dermique Clobetasol propiomate 12/06/2024
Vitamine Forme dermique Nicotinamide 12/06/2024
Divers Forme dermique Cafeine 04/06/2024
Anticancéreux injectable Pevonedistat 03/06/2024
Antibiotique Solution buvable Clofazimine 15/04/2024
Antiinflammatoire Forme dermique Diclofenac 08/04/2024
Divers injectable Angiotensin II 02/04/2024
Divers injectable Ranibizumab 08/03/2024
Nouveautés - Références bibliographiques  
Date de saisie
4919 Dostarlimab (Jemperli®) – Résumé des caractéristiques du produits 03/03/2025
4905 Characterization of Liquid Dosage Forms of Atenolol and Enalapril Maleate for Oral and Enteral Feeding Administration Pharmaceuticals 15/01/2025
4886 Physicochemical and Microbiological Stability of Ursodiol Oral Compounded Suspensions. J Pediatr Pharmacol Ther 11/12/2024
4884 Stability of Diluted Desmopressin Acetate Intranasal Solution at 0.01 mg/mL. Int J Pharm Compound 06/12/2024
4878 Compatibility of Cetirizine Hydrochloride, Dutasteride, Hydrocortisone Acetate, Nicotinamide, Porgesterone, and Pyridoxine Hydrochloride in TrichoSol, A Natural Vehicle for Hair Solutions. Int J Pharm Compound 08/11/2024
4879 Compatibility of Active Pharmaceutical Ingredients in Cleoderm: A Comprehensive Study for Enhanced Topical Dermatological Treatments. Int J Pharm Compound 08/11/2024
4880 Stability of Allopurinol in Extemporaneously Compounded Oral Suspensions with Oral Mix and Oral Mix SF. Int J Pharm Compound 08/11/2024
4867 Etude des compatibilités entre la nalbuphine et d'autres principes actifs pour optimiser leur administration en service de pédiatrie. CSH (SNPHPU) Congress sept 2024 17/10/2024
4868 Etude de la stabilité physico-chimique de solutions de 5-fluorouracile diluées en poches polyoléfine a des concentrations comprises entre 9 et 15 mg/ml. CSH (SNPHPU) Congress sept 2024 17/10/2024
4865 Cyclophosphamide REDDY PHARMA 2000 mg/4 ML, solution à diluer pour solution injectable/perfusion. - Résumé des caractéristiques du produit. Dr REDDY laboratoire 01/10/2024
4863 Physical Compatibility Between Intravenous Magnesium Sulfate and Potassium or Sodium Phosphate in a Pediatric Intensive Care Unit. Hosp Pharm 25/09/2024
4855 Physical compatibility of colistin with analgesics during simulated Y-site administration. Am J Hosp Pharm 04/09/2024
4857 Physicochemical and Microbiological Stability of Compounded Clonidine Hydrochloride Oral iquid Dosage Forms in PCCA Base, SuspendIt®. Int J Pharm Compound 04/09/2024
4858 Physical Compatibility of Intravenous Ondansetron Hydrochloride and Nafcillin Sodium. Int J Pharm Compound 04/09/2024
4859 Physicochemical and Microbiological Stability of Compounded Bethanechol Chloride Oral Suspensions in PCCA Base, SuspendIt® Int J Pharm Compound 04/09/2024
4862 Erwinase, 10,000 IU/vial, Powder for solution for injection/infusion - Summary of Product Characteristics Updated 04-Jul-2022. Porton Biopharma Limited 04/09/2024
4852 KEYTRUDA 25 mg/mL solution à diluer pour perfusion. Résumé des caractéristiques du produit. Merck Sharp & Dohme B.V. 25/08/2024
4849 Formulation and Stability of a 1% Clarithromycin-Based Topical Skin Cream: A New Option to Treat Buruli Ulcers? Pharmaceuticals 22/08/2024
4850 The Infusion of Piperacillin/Tazobactam with an Elastomeric Device: A Combined 24-H Stability Study and Drug Solution Flow Rate Analysis. Pharmaceuticals 22/08/2024
4851 Long-term stability of esketamine in polypropylene syringes at 5 ± 3°C. EJHP 22/08/2024
4846 Chemical Stability of Lorazepam Oral Solution Repackaged in Plastic Oral Syringes at Room and Refrigerated Temperature. Hosp Pharm 03/07/2024
4843 Y-Site Compatibility Studies of Ketoprofen with Parenteral Nutrition Admixtures for Central and Peripheral Administration. Pharmaceutics 30/06/2024
4842 Harmonising IV Oxycodone with Paediatric Perioperative Medications: A Compatibility Study Through Y-Type Connectors Drug Design Dev Ther 28/06/2024
4835 Plasma-Lyte 148 and Plasma-Lyte 148 + 5% glucose compatibility with commonly used critical care drugs. Intensive Care Medecine Experimental 16/06/2024
4837 Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings. Eur J Clin Pharmacol 16/06/2024
4828 The Physical Compatibility of Glycopyrrolate and Rocuronium. Anesth Prog 15/06/2024
4831 Frequently acquired drugs in neonatal intensive care and their physical compatibility. Acta Paediatr 15/06/2024
4832 Co‑administration of drugs with parenteral nutrition in the neonatal intensive care unit—physical compatibility between three components. Eur J Pedia 15/06/2024
4824 Physicochemical stability of pevonedistat at 50, 100 and 200 µg/mL diluted in 0.9% sodium chloride and at 10 mg/mL in partially used vials. EJHP 03/06/2024
4825 Physicochemical and microbiological stability study of two new preservative-free methylprednisolone eye drops. Farm Hosp 03/06/2024

  Mentions Légales